Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%
Information source: Coria Laboratories, Ltd.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Atralin (tretinoin) Gel, 0.05% (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Coria Laboratories, Ltd. Official(s) and/or principal investigator(s):
Joseph Stanfiled, MS, Principal Investigator, Affiliation: Suncare Laboratories
Summary
To assess the potential of tretnoin gel 0. 05% to produce phototoxic reactions, measured as
skin reactions 24 and 48 hours after UV radiation of drug on skin.
Clinical Details
Official title: Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%
Study design: Other, Randomized, Single Blind (Outcomes Assessor), Single Group Assignment
Primary outcome: UV induced skin sensitization
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Normal healthy volunteers
- 18 years of age or older
Exclusion Criteria:
- Less than 18 years of age
Locations and Contacts
Suncare Research Laboratories, Winston-Salem, North Carolina 27106, United States
Additional Information
Starting date: January 2008
Ending date: February 2008
Last updated: March 26, 2008
|
